DHAP (chemotherapy)


DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab it is called R-DHAP or DHAP-R.
-DHAP regimen consists of:
  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. 'examethasone, a glucocorticoid hormone
  3. 'igh-dose 'ra-C - cytarabine, an antimetabolite;
  4. 'latinol, a platinum-based antineoplastic, also an alkylating antineoplastic agent.

    Dosing regimen